Torrent Pharmaceuticals Ltd.

Ahmedabad-based Torrent Pharmaceuticals spent 6 per cent of its total revenue during the FY20-21, amounting to Rs 487 crore. The company’s state-of-the art R&D Centre at Bhat near Ahmedabad has one of the most advanced infrastructure for both basic and applied research to support all activities related to generic, new drug discovery, API process development, formulation development and value-added generics. Torrent’s Research Centre houses 700+ inquisitive minds that have identified potentially transformative therapy areas for the New Chemical Entities (NCE) and Novel Drug Delivery Systems (NDDS) pipeline as R&D priority areas. Besides cardiovascular, central nervous system, gastro-intestinal and women healthcare, the company also has significant presence in diabetology, pain management, gynaecology, oncology and antiinfective segments.

Key Highlights of FY20-21

■ Partnered with Eli Lilly and Company to manufacture and commercialise ‘Baricitinib’ (an emergency use approved drug given in combination with Remdesivir for COVID-19) in India.

■ Filed 12 Abbreviated New Drug Applications (ANDAs) with USFDA.

■ Started shifting the production of several drugs from the flagship Indrad facility to Dahej and Baddi units.

Around 85 per cent of Torrent Pharma’s revenue is derived from four core markets, namely India, United States, Germany and Brazil. India continues to be the largest market, contributing to over 45 per cent of revenue. The underlying growth in our core markets of India, Brazil and Germany has been strong and continues to outperform the market. The growth in the US was impacted due to lack of new approvals, pending re-inspection of facilities by USFDA. Also, we are building a comprehensive pipeline for its liquids and oncology facilities.

- SAMIR MEHTA

Executive Chairman, Torrent Pharmaceuticals Limited